@article{1f8fb3e312b441c5a861a34be22e3aff,
title = "Comparison of variables associated with cerebrospinal fluid neurofilament, total-tau, and neurogranin",
abstract = "Introduction: Three cerebrospinal fluid (CSF) markers of neurodegeneration (N) (neurofilament light [NfL], total-tau [T-tau], and neurogranin [Ng]) have been proposed under the AT(N) scheme of the National Institute on Aging–Alzheimer's Association Research Framework. Methods: We examined, in a community-based population (N = 777, aged 50–95) (1) what variables were associated with each of the CSF (N) markers, and (2) whether the variables associated with each marker differed by increased brain amyloid. CSF T-tau was measured with an automated electrochemiluminescence Elecsys immunoassay; NfL and Ng were measured with in-house enzyme-linked immunosorbent assays. Results: Multiple variables were differentially associated with CSF NfL and T-tau levels, but not Ng. Most associations were attenuated after adjustment for age and sex. T-tau had the strongest association with cognition in the presence of amyloidosis, followed by Ng. Variables associations with NfL did not differ by amyloid status. Discussion: Understanding factors that influence CSF (N) markers will assist in the interpretation and utility of these markers in clinical practice.",
keywords = "Cerebrospinal fluid, Community-based population, Neurodegeneration, Neurofilament light chain, Neurogranin, Total-tau, Vascular factors",
author = "Mielke, {Michelle M.} and Syrjanen, {Jeremy A.} and Kaj Blennow and Henrik Zetterberg and Ingmar Skoog and Prashanthi Vemuri and Machulda, {Mary M.} and Jonathan Graff-Radford and Knopman, {David S.} and Jack, {Clifford R.} and Petersen, {Ronald C.} and Silke Kern",
note = "Funding Information: Funding: This study was supported by funding from the National institutes of Health / National Institute on Aging grants U01 AG006786 , R01 AG011378 , R01 AG041851 , R01 AG049704 , and R01 AG034676 . Additional funding came from the GHR Foundation , the Swedish Research Council ( 2015-02830 ), the European Research Council ( 681712 ), the Knut and Alice Wallenberg Foundation , Frimurarestiftelsen, the Olav Thon Foundation, Swedish State Support for Clinical Research (ALF V{\"a}stra G{\"o}talandsregionen), the Swedish state under the agreement between the Swedish Government and the county councils, the ALF-agreement (ALFGBG-813921, ALFGBG-65930, ALFGBG-716681, ALFGBG-771071), the Torsten S{\"o}derberg Foundation, the Swedish Alzheimer Foundation, Hj{\"a}rnfonden Sweden, Stiftelsen Demensfonden, Stiftelsen Hjalmar Svenssons Forskningsfond, and Stiftelsen Wilhelm och Martina Lundgrens Vetenskapsfond. Funding Information: M.M. Mielke served as a consultant to Eli Lilly and receives research support from the National Institutes of Health (R01 AG49704, P50 AG44170, U01 AG06786, and RF1 AG55151), Department of Defense (W81XWH-15-1), and unrestricted research grants from Biogen. K.B. has served as a consultant or at advisory boards for Alzheon, BioArctic, Biogen, Eli Lilly, Fujirebio Europe, IBL International, Merck, Novartis, Pfizer, and Roche Diagnostics, and is a cofounder of Brain Biomarker Solutions in Gothenburg AB, a GU Venture-based platform company at the University of Gothenburg. H. Z. has served at advisory boards for Eli Lilly, Roche Diagnostics and Wave, has received travel grants from Teva and is a cofounder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. I.S. has been an advisor and speaker for Takeda. D.S.K. serves on a Data Safety Monitoring Board for Lundbeck Pharmaceuticals and for the DIAN study; is an investigator in clinical trials sponsored by Biogen, Lilly Pharmaceuticals, and the Alzheimer's Disease Cooperative Study; and receives research support from the National Institutes of Health. C.R.J. has provided consulting services for Eli Lilly. He receives research funding from the National Institutes of Health, and the Alexander Family Alzheimer's Disease Research Professorship of the Mayo Clinic. R.C.P. is a consultant for Roche, Inc, Merck, Inc, Biogen, Inc, Genentech, Inc, and GE Healthcare. He receives research support from the National Institutes of Health. J.G.-R., M.M. Machulda, P.V., J.A.S., and S.K. have nothing to disclose.Funding: This study was supported by funding from the National institutes of Health/National Institute on Aging grants U01 AG006786, R01 AG011378, R01 AG041851, R01 AG049704, and R01 AG034676. Additional funding came from the GHR Foundation, the Swedish Research Council (2015-02830), the European Research Council (681712), the Knut and Alice Wallenberg Foundation, Frimurarestiftelsen, the Olav Thon Foundation, Swedish State Support for Clinical Research (ALF V?stra G?talandsregionen), the Swedish state under the agreement between the Swedish Government and the county councils, the ALF-agreement (ALFGBG-813921, ALFGBG-65930, ALFGBG-716681, ALFGBG-771071), the Torsten S?derberg Foundation, the Swedish Alzheimer Foundation, Hj?rnfonden Sweden, Stiftelsen Demensfonden, Stiftelsen Hjalmar Svenssons Forskningsfond, and Stiftelsen Wilhelm och Martina Lundgrens Vetenskapsfond. Funding Information: M.M. Mielke served as a consultant to Eli Lilly and receives research support from the National Institutes of Health ( R01 AG49704 , P50 AG44170 , U01 AG06786 , and RF1 AG55151 ), Department of Defense (W81XWH-15-1), and unrestricted research grants from Biogen . K.B. has served as a consultant or at advisory boards for Alzheon, BioArctic, Biogen, Eli Lilly, Fujirebio Europe, IBL International, Merck, Novartis, Pfizer, and Roche Diagnostics, and is a cofounder of Brain Biomarker Solutions in Gothenburg AB, a GU Venture-based platform company at the University of Gothenburg. H. Z. has served at advisory boards for Eli Lilly, Roche Diagnostics and Wave, has received travel grants from Teva and is a cofounder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. I.S. has been an advisor and speaker for Takeda. D.S.K. serves on a Data Safety Monitoring Board for Lundbeck Pharmaceuticals and for the DIAN study; is an investigator in clinical trials sponsored by Biogen, Lilly Pharmaceuticals, and the Alzheimer's Disease Cooperative Study; and receives research support from the National Institutes of Health . C.R.J. has provided consulting services for Eli Lilly. He receives research funding from the National Institutes of Health , and the Alexander Family Alzheimer's Disease Research Professorship of the Mayo Clinic . R.C.P. is a consultant for Roche, Inc, Merck, Inc, Biogen, Inc, Genentech, Inc, and GE Healthcare. He receives research support from the National Institutes of Health . J.G.-R., M.M. Machulda, P.V., J.A.S., and S.K. have nothing to disclose. Publisher Copyright: {\textcopyright} 2019 the Alzheimer's Association",
year = "2019",
month = nov,
doi = "10.1016/j.jalz.2019.07.009",
language = "English (US)",
volume = "15",
pages = "1437--1447",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "11",
}